Logo image of CMPS

COMPASS PATHWAYS PLC (CMPS) Stock Fundamental Analysis

NASDAQ:CMPS - Nasdaq - US20451W1018 - ADR - Currency: USD

4.21  -0.33 (-7.27%)

After market: 4.24 +0.03 (+0.71%)

Fundamental Rating

2

CMPS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While CMPS seems to be doing ok healthwise, there are quite some concerns on its profitability. CMPS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CMPS has reported negative net income.
In the past year CMPS has reported a negative cash flow from operations.
In the past 5 years CMPS always reported negative net income.
In the past 5 years CMPS always reported negative operating cash flow.
CMPS Yearly Net Income VS EBIT VS OCF VS FCFCMPS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

CMPS has a Return On Assets (-58.35%) which is in line with its industry peers.
CMPS has a Return On Equity of -74.77%. This is comparable to the rest of the industry: CMPS outperforms 54.71% of its industry peers.
Industry RankSector Rank
ROA -58.35%
ROE -74.77%
ROIC N/A
ROA(3y)-37.72%
ROA(5y)-40.66%
ROE(3y)-42.73%
ROE(5y)-77.91%
ROIC(3y)N/A
ROIC(5y)N/A
CMPS Yearly ROA, ROE, ROICCMPS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CMPS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPS Yearly Profit, Operating, Gross MarginsCMPS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, CMPS has more shares outstanding
The number of shares outstanding for CMPS has been increased compared to 5 years ago.
The debt/assets ratio for CMPS is higher compared to a year ago.
CMPS Yearly Shares OutstandingCMPS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
CMPS Yearly Total Debt VS Total AssetsCMPS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

CMPS has an Altman-Z score of 0.68. This is a bad value and indicates that CMPS is not financially healthy and even has some risk of bankruptcy.
CMPS's Altman-Z score of 0.68 is fine compared to the rest of the industry. CMPS outperforms 64.65% of its industry peers.
CMPS has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CMPS (0.14) is worse than 69.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 0.68
ROIC/WACCN/A
WACCN/A
CMPS Yearly LT Debt VS Equity VS FCFCMPS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

CMPS has a Current Ratio of 8.91. This indicates that CMPS is financially healthy and has no problem in meeting its short term obligations.
CMPS's Current ratio of 8.91 is fine compared to the rest of the industry. CMPS outperforms 75.67% of its industry peers.
A Quick Ratio of 8.91 indicates that CMPS has no problem at all paying its short term obligations.
The Quick ratio of CMPS (8.91) is better than 75.84% of its industry peers.
Industry RankSector Rank
Current Ratio 8.91
Quick Ratio 8.91
CMPS Yearly Current Assets VS Current LiabilitesCMPS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.06% over the past year.
EPS 1Y (TTM)15.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CMPS will show a small growth in Earnings Per Share. The EPS will grow by 4.28% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-0.98%
EPS Next 2Y8.96%
EPS Next 3Y7.09%
EPS Next 5Y4.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMPS Yearly Revenue VS EstimatesCMPS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CMPS Yearly EPS VS EstimatesCMPS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CMPS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CMPS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPS Price Earnings VS Forward Price EarningsCMPS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMPS Per share dataCMPS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.96%
EPS Next 3Y7.09%

More info and screens

0

5. Dividend

5.1 Amount

CMPS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPASS PATHWAYS PLC

NASDAQ:CMPS (2/21/2025, 8:00:00 PM)

After market: 4.24 +0.03 (+0.71%)

4.21

-0.33 (-7.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)02-26 2025-02-26/amc
Inst Owners43.32%
Inst Owner Change-9.14%
Ins Owners1.84%
Ins Owner Change-23.09%
Market Cap389.15M
Analysts83.75
Price Target19.61 (365.8%)
Short Float %5.78%
Short Ratio4.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.48%
Min EPS beat(2)-4.82%
Max EPS beat(2)3.87%
EPS beat(4)1
Avg EPS beat(4)-17.34%
Min EPS beat(4)-57.46%
Max EPS beat(4)3.87%
EPS beat(8)3
Avg EPS beat(8)-13.77%
EPS beat(12)6
Avg EPS beat(12)-4.1%
EPS beat(16)9
Avg EPS beat(16)1.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.57%
PT rev (3m)-45.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.18%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.02
P/tB 2.02
EV/EBITDA N/A
EPS(TTM)-2.2
EYN/A
EPS(NY)-1.94
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0
BVpS2.09
TBVpS2.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.35%
ROE -74.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.72%
ROA(5y)-40.66%
ROE(3y)-42.73%
ROE(5y)-77.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.71%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.91
Quick Ratio 8.91
Altman-Z 0.68
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)130.81%
Cap/Depr(5y)158.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.42%
EPS Next Y-0.98%
EPS Next 2Y8.96%
EPS Next 3Y7.09%
EPS Next 5Y4.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-35.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-35.25%
EBIT Next 3Y-14.5%
EBIT Next 5Y1.05%
FCF growth 1Y-26.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.5%
OCF growth 3YN/A
OCF growth 5YN/A